Entity family

Browse funders

Organisations named as supporting, sponsoring, or funding research. Examples include Wellcome, NIHR, research councils.

5,089articles mentioning funders

9,137funder mentions

3,238distinct funders extracted

0%of mentions human-reviewed

Filter articles

JournalContent resourceEvidence policyAutomated confidence floorArticles per pageReset filters

“Reviewed + threshold” includes every confirmed correction plus unreviewed proposals at or above the selected model score.

All extracted funders

Showing 541–600 of 3,238, ordered by supporting articles. Choose a funder to see its evidence.

View all 3,238 funders on one page

Articles mentioning funders

5,089 articles · page 330 of 425

502 Profiling of the neoantigen-specific T cell response after adjuvant TG4050 individualized therapeutic vaccination in a randomized phase I trial for locally advanced resected HPV-negative HNSCC

jitc · abstract · 2025-11-04 · 1 matching annotations

84.0%

NCT04183166 TG4050 Mayo Clinic HNSCC South Central - Oxford

…Background In the phase I trial TG4050.02 ( NCT04183166) evaluating TG4050 in resected, locally advanced HNSCC patients…

510 Dynamic tumor and immune response to neoadjuvant nivolumab with chemotherapy in diffuse pleural mesothelioma

jitc · abstract · 2025-11-04 · 1 matching annotations

86.0%

NCT04162015 nivolumab Diffuse pleural mesothelioma pemetrexed cisplatin carboplatin platinum P/D

…exed prior to P/D (2 cycles) for patients with resectable DPM ( NCT04162015).Methods To comprehensively assess tumor and immune microenviro…

511 Specific TCR clones associated with better pathological response for early stage NSCLC patients treated with neoadjuvant immunotherapy: results from CTONG1804

jitc · abstract · 2025-11-04 · 1 matching annotations

94.6%

Bristol-Myers Squibb neoadjuvant immunotherapy nivolumab EGFR-mutant NSCLC chemotherapy CTONG1104

…and families involved in this study. This work was supported by Bristol-Myers Squibb, Guangdong Provincial Key Lab of Translational Medicine in Lung…

513 Advanced analytics identify a differential immune response to CAN-2409+valacyclovir in non-squamous vs squamous NSCLC, linked to improved survival in patients with progressive ICI-refractory NSCLC

jitc · abstract · 2025-11-04 · 1 matching annotations

75.8%

Foundation for the National Institutes of Health, Inc.CAN-2409 docetaxel NSCLC sacituzumab govitecan valacyclovir

…oject was made possible through funding support provided to the Foundation for the National Institutes of Health, Inc. (FNIH) by: AbbVie Inc., Amgen Inc., Boehringer-Ingelheim Pharma…

518 Capivasertib, an AKT inhibitor, remodels the tumor microenvironment to synergize with combination therapy of olaparib and durvalumab in susceptible advanced/metastatic solid cancers

jitc · abstract · 2025-11-04 · 1 matching annotations

85.2%

AstraZeneca durvalumab capivasertib Durva olaparib Ola Cap relapse/refractory solid cancers

…ing macrophages and stromal cells are underway.Acknowledgements AstraZeneca’s support is gratefully acknowledgedTrial Registration NCT03772…

520 Safety and tolerability of ASP1012, an oncolytic virus, in adults with locally advanced or metastatic solid tumors: Results from a first-in-human, phase 1, open-label, dose-escalation study

jitc · abstract · 2025-11-04 · 1 matching annotations

79.0%

Astellas Pharma Inc.ASP1012 la/m solid tumors advanced solid tumors Oxford PharmaGenesis Inc.

…uding 3×10 9 pfu/dose.Acknowledgements This study was funded by Astellas Pharma Inc. Medical writing support, conducted in accordance with Good Publ…

527 Primary results with long-term follow up of a phase II study of neoadjuvant and adjuvant cemiplimab in high-risk resectable cutaneous squamous cell carcinoma

jitc · abstract · 2025-11-04 · 1 matching annotations

78.6%

IRB00115160 cemiplimab Emory University metastatic cutaneous squamous cell carcinoma (CSCC)

…proval The study was approved by the Emory IRB (approval number IRB00115160) and participants gave informed consent to take part in this st…

530 CD40 agonist mitazalimab + mFOLFIRINOX in patients with metastatic pancreatic ductal adenocarcinoma: dose characterization based on exposure response and biomarker analysis from the OPTIMIZE-1 study

jitc · abstract · 2025-11-04 · 1 matching annotations

90.9%

FDA Mitazalimab mFOLFIRINOX

… Journal for ImmunoTherapy of Cancer 2024;12(Suppl 2):A677–A678.FDA. Optimizing the dose of human prescription drugs and biological…

534 A Phase 1 dose-escalation and expansion study evaluating the safety, efficacy, and pharmacokinetics of EVOLVE104 in subjects with advanced urothelial and squamous cell carcinomas

jitc · abstract · 2025-11-04 · 1 matching annotations

84.1%

FDA EVOLVE104 EIU-104101 urothelial carcinoma squamous cell carcinomas Cohort B Cohort A EVOLVE TCEs transitional cell carcinomas of the urinary tract locally advanced or metastatic solid tumors

…g.Ethics Approval Study EIU-104101 is currently under review by FDA and will only begin enrollment upon clearance from relevant hea…

542 Peritoneal mononuclear phagocytes show distinct dynamics in gastrointestinal cancer peritoneal metastasis patients and contribute to the responses of intraperitoneal paclitaxel chemotherapy

jitc · abstract · 2025-11-04 · 1 matching annotations

93.3%

American Surgical Association Research Award Appendiceal cancer MD Anderson Cancer Center Barnes-Jewish Hospital paclitaxel University of Texas MD Anderson Cancer Center colorectal cancer Washington University Institutional Review Board

…cy.Acknowledgements This work was supported by funding from the American Surgical Association Research Award (Dr. Beth A. Helmink), NIH grant R37AI049653 (Dr. Gwendalyn J. …

547 A phase 1b study of intraperitoneal cytokine-induced memory-like (CIML) natural killer (NK) cell therapy in platinum resistant ovarian cancer

jitc · abstract · 2025-11-04 · 1 matching annotations

94.0%

PHASE ONE Foundation ECOG Performance Status Dana-Farber Cancer Institute IL-12 myeloid leukemia IL-15 IL-18 PROC pembrolizumab Dana-Farber/Harvard Cancer Center+6 more

…uable. The authors are deeply grateful for funding support from PHASE ONE Foundation and from Pan-Mass Challenge Team Ovarian Cancer.References Disi…

550 Single cell RNA sequencing reveals immune subset differences between immunotherapy-resistant and untreated head and neck squamous cell carcinoma

jitc · abstract · 2025-11-04 · 1 matching annotations

75.6%

Mount Sinai PPHS IRB HNSCC immunotherapy Mount Sinai Institutional Biorepository Head and neck squamous cell carcinoma (HNSCC)

…drivers of immunotherapy resistance among HNSCC.Ethics Approval Mount Sinai PPHS IRB approved STUDY-21-01683…